Shire Set to Cut U.K. Research Jobs as CEO Overhauls Operations

Shire Plc (SHP) plans to cut U.K. research jobs and will move its Swiss operations as part of a reorganization at the drugmaker led by Chief Executive Officer Flemming Ornskov.

About 180 employees at Shire’s U.K. headquarters in Basingstoke may be affected, a spokesman said by e-mail. The company also plans to move its Swiss operations from Eysins to Zug and has begun consultations with workers, the Dublin-based company said today in a statement on its website.

Shire plans to “discontinue a number of programs outside of rare diseases” and will focus on drug projects that have the best chance of clinical and commercial success, the company said. This will result in a significant decrease in the amount of research and development in Basingstoke, England, the company said. A small number of functional roles may also be affected, the company said.

Shire was little changed at 2,831 pence at 1:35 p.m. in London trading. The stock rose to a record this month, helped by earlier-than-expected positive data on its best-selling Vyvanse pill to treat binge-eating disorder.

Ornskov, who took over in May, has said his overhaul, dubbed One Shire, has already streamlined operations and reduced costs.

“We are making Shire a leaner and more productive organization with a reset cost base,” he said on Oct. 24 after reporting third-quarter earnings.

About 520 of Shire’s 5,500 employees are based in the U.K., the company said.

To contact the reporter on this story: Trista Kelley in London at tkelley2@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.